Novel conjugate meets primary endpoint

The phase 3 TULIP trial, investigating the novel antibody drug conjugate trastuzumab duocarmazine, met its primary endpoint of extended median progression-free survival (PFS) in HER2-positive breast cancer patients, compared with physician’s choice, in the third-line setting. These results were presented in the second Presidential Symposium. Trastuzumab duocarmazine is an antibody drug conjugate that targets the HER2 protein with trastuzumab to deliver the cytotoxin duocarmycin after internalisation. Presented by Dr Cristina Saura (Vall d’Hebron Institute of Oncology, Spain), the TULIP trial (NCT03262935) aimed to demonstrate that trastuzumab duocarmazine (1.2 mg/kg every 3 weeks) is superior to physician's choice of treatment in prolonging PFS per blinded independent central review, as its primary endpoint [1]. Eligible patients were randomly assigned 2:1 t...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 19 November, 2021